Understanding Hodgkin Lymphoma: Relapsed/Refractory

Hodgkin lymphoma (HL), also known as Hodgkin disease, is not as common as non-Hodgkin lymphoma (NHL). Although HL can occur in both children and adults, it is most commonly diagnosed in young adults between the ages of 20 and 34 years.

HL has been studied more than any other type of lymphoma, and because of the treatment advances over the past few decades, five-year survival rates have improved.

The presence of Reed-Sternberg cells is necessary in the diagnosis of HL, although other inflammatory cell types are present. HL usually starts in the lymph nodes; however, it often spreads from one lymph node to another and can also involve other organs.

Common signs and symptoms of HL include swelling of the lymph nodes (which is often but not always painless), fever, night sweats, unexplained weight loss, itching, and lack of energy. While most people who have these complaints do not have HL, anyone with persistent symptoms should see a physician to make sure that lymphoma is not present.

**COMMON TYPES OF HL**

The two main classifications of Hodgkin lymphoma are classic HL (cHL), which accounts for almost all cases (93 percent) of HL, and nodular lymphocyte-predominant HL.

**The Four Subtypes of cHL are:**
- Nodular sclerosis
- Mixed cellularity cHL
- Lymphocyte-depleted cHL
- Lymphocyte-rich cHL

Treatment choices for patients with nodular lymphocyte-predominant HL differ from those available to patients with cHL.

**RELAPSED OR REFRACTORY**

For patients who *relapse* (disease returns after treatment) or become refractory (does not respond to treatment), secondary therapies are often successful in providing another *remission* (disappearance of signs and symptoms) and may even cure the disease. For cHL, most relapses typically occur within the first three years following diagnosis, although some relapses occur much later.

**TREATMENT OPTIONS**

A number of treatment options are available for patients with relapsed or refractory HL. Exactly what type of treatment is prescribed for individual patients depends on several factors, including the timing of the relapse, age and overall health of the patient, scope of disease, and previous therapies received.

The standard secondary treatment for the majority of patients consists of *systemic* (throughout the body) therapy, usually followed by *autologous stem cell transplantation* (in which a patient’s own stem cells are infused after high-dose chemotherapy) in younger patients without other significant health conditions. Involved-site radiation therapy (ISRT) may also be used. For more information on transplantation, view the *Understanding the Stem Cell Transplantation Process* publication on the Lymphoma Research Foundation’s (LRF’s) website at lymphoma.org/publications.

There are a variety of single-agent and combination therapy regimens that may be used for relapsed/refractory HL, including:
- Brentuximab vedotin (Adcetris)
- Bendamustine (Treanda)
- Nivolumab (Opdivo)
- Pembrolizumab (Keytruda)
- DHAP (dexamethasone, cisplatin, and cytarabine)
• ESHAP (etoposide, methylprednisolone, cisplatin, and cytarabine)
• GVD (gemcitabine, vinorelbine, and liposomal doxorubicin)
• ICE (ifosfamide, carboplatin, and etoposide)
• IGEV (ifosfamide, gemcitabine, and vinorelbine)

**TREATMENTS UNDER INVESTIGATION**

In addition to conventional chemotherapies, there are several new agents currently being tested in clinical trials:

- Anti-CD30-CAR T cells
- Atezolizumab [Tecentriq]
- Carfilzomib [Kyprolis]
- Everolimus [Afinitor]
- Ibrutinib [Imbruvica]
- Lenalidomide [Revlimid]
- Mocetinostat [MGCD103]
- Ruxolitinib [Jakafi]
- Umbralisib

It is critical to remember that today’s scientific research is continuously evolving. Treatment options may change as new treatments are discovered and current treatments are improved. Therefore, it is important that patients check with their physician or with LRF for any treatment updates that may have recently emerged.

**FOLLOW-UP**

Patients with lymphoma should have regular visits with a physician who is familiar with their medical history and the treatments they have received. Medical tests (such as blood tests and computed tomography [CT]/ positron emission tomography [PET] scans) may be required at various times during remission to evaluate the need for additional treatment.

Patients and their caregivers are encouraged to keep copies of all medical records and test results as well as information on the types, amounts, and duration of all treatments received. This documentation will be important for keeping track of any effects resulting from treatment or potential disease recurrences. LRF’s award-winning [Focus on Lymphoma mobile app](lymphoma.org/mobileapp) and [Lymphoma Care Plan](lymphoma.org/publications)

---

**Clinical Trials Information Service**

Clinical trials are crucial in identifying effective drugs and determining optimal doses for patients with lymphoma. Patients interested in participating in a clinical trial should view the Understanding Clinical Trials fact sheet on LRF’s website at www.lymphoma.org, talk to their physician, or contact the LRF Helpline for an individualized clinical trial search by calling 800-500-9976 or emailing helpline@lymphoma.org.

**Education Resources**

- In-Person Education Programs
- Focus on Lymphoma Mobile App
- Patient Publications
- Podcasts
- Webinars
- YouTube Videos

**Support Services**

- Financial Assistance Program
- LRF Helpline
- Lymphoma Support Network
- Stories of Hope

---

Contact LRF:  
Helpline: 800-500-9976  
Email: helpline@lymphoma.org  
[www.lymphoma.org](http://www.lymphoma.org)

Medical reviewers:  
Ann S. LaCasce, MD, MMSc  
Dana-Farber Cancer Institute

Supported through grants from:  
[Logos](#)

© 2019 Understanding Lymphoma factsheet series is published by the Lymphoma Research Foundation (LRF) for the purpose of informing and educating readers. Facts and statistics were obtained using published information, including data from the Surveillance, Epidemiology, and End Results (SEER) Program. Because each person’s body and response to treatment is different, no individual should self-diagnose or embark upon any course of medical treatment without first consulting with his or her physician. The medical reviewer, the medical reviewer’s institution, and LRF are not responsible for the medical care or treatment of any individual.